Drug Transporter (DT) Information
General Information and Variability Data of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0031 | ||||
Gene Name | SLCO2B1 | ||||
Protein Name | Organic anion transporting polypeptide 2B1 | ||||
Synonyms | KIAA0880; OATP-B; OATP-RP2; OATP2B1; OATPB; OATPRP2; Organic anion transporter B; Organic anion transporter polypeptide-related protein 2; SLC21A9; SLCO2B1; Solute carrier family 21 member 9; Solute carrier organic anion transporter family member 2B1 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
DT Family | Organo Anion Transporter (OAT) Family ; | ||||
Tissue Specificity | Isoform 1 has it's highest expression inbrain, it is the major form expressed in duodenum, kidney,placenta, and skeletal muscle. Isoform 3 predominates in liver. | ||||
Function | This Na(+)-independent transporter mediates the transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost. | ||||
Disease(s) | Diabetes [ICD-11: 5A10-5A14] | ||||
Dry eye disease [ICD-11: 9A79] | |||||
Dyslipidaemias [ICD-11: 5C8Z] | |||||
High blood pressure [ICD-11: BA00] | |||||
Human immunodeficiency virus infection [ICD-11: 1C62.Z] | |||||
Medical abortion [ICD-11: JA00.1] | |||||
Open angle glaucoma [ICD-11: 9C61] | |||||
Pulmonary arterial hypertension [ICD-11: BB01.0] | |||||
Renal cell carcinoma [ICD-11: 2C90] | |||||
Genetic Polymorphisms & Epigenetic Regulations of DT | |||||
Species-, Tissue- and Disease-specific Protein Abundances of DT | |||||
Exogenous Factor Altering DT Activity | |||||
Approved Drug(s) Transported by This DT | Abiraterone acetate | Drug Info | Prostate cancer [ICD-11: 2C82] | Approved | [1] |
Aliskiren fumarate | Drug Info | High blood pressure [ICD-11: BA00] | Approved | [2] | |
Atorvastatin | Drug Info | Hyperlipidaemia [ICD-11: 5C8Z] | Approved | [3] | |
Bosentan | Drug Info | Pulmonary arterial hypertension [ICD-11: BB01.0] | Approved | [4] | |
Cerivastatin | Drug Info | Hyperlipidaemia [ICD-11: 5C8Z] | Approved | [5] | |
Dehydroepiandrosterone sulfate | Drug Info | Dyspareunia [ICD-11: GA12] | Approved | [6] | |
Digoxin | Drug Info | Arrhythmias [ICD-11: BC60-BC9Z] | Approved | [7] | |
Dinoprostone | Drug Info | Medical abortion [ICD-11: JA00.1] | Approved | [8] | |
Eltrombopag | Drug Info | Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] | Approved | [9] | |
Estrone sulfate | Drug Info | Menopausal symptoms [ICD-11: MF32] | Approved | [10] | |
Etoposide | Drug Info | Testicular cancer [ICD-11: 2C80] | Approved | [11] | |
Fexofenadine | Drug Info | Allergic rhinitis [ICD-11: CA08.0] | Approved | [12] | |
Fluvastatin | Drug Info | Hypercholesterolemia [ICD-11: 5C80.0] | Approved | [10] | |
Glibenclamide | Drug Info | Diabetes [ICD-11: 5A10-5A14] | Approved | [13] | |
L-glutamic acid | Drug Info | Schizophrenia [ICD-11: 6A20] | Approved | [14] | |
Latanoprost | Drug Info | Open angle glaucoma [ICD-11: 9C61] | Approved | [15] | |
Latanoprostene bunod | Drug Info | Renal cell carcinoma [ICD-11: 2C90] | Approved | [15] | |
Lifitegrast | Drug Info | Dry eye disease [ICD-11: 9A79] | Approved | [16] | |
Mesalazine | Drug Info | Recurrent ventricular fibrillation [ICD-11: BC71.1] | Approved | [17] | |
Montelukast | Drug Info | Asthma [ICD-11: CA23] | Approved | [18] | |
Pemetrexed | Drug Info | Malignant pleural mesothelioma [ICD-11: 2C26.0] | Approved | [19] | |
Pitavastatin | Drug Info | Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z] | Approved | [20] | |
Pitavastatin calcium | Drug Info | Dyslipidaemias [ICD-11: 5C8Z] | Approved | [21] | |
Pravastatin | Drug Info | Hypercholesterolemia [ICD-11: 5C80.0] | Approved | [22] | |
Ritonavir | Drug Info | Human immunodeficiency virus infection [ICD-11: 1C62.Z] | Approved | [23] | |
Rocuronium | Drug Info | Muscle relaxant [ICD-11: XM31L2] | Approved | [7] | |
Rosuvastatin | Drug Info | Hypercholesterolemia [ICD-11: 5C80.0] | Approved | [24] | |
Sulfasalazine | Drug Info | Rheumatoid arthritis [ICD-11: FA20] | Approved | [25] | |
Telmisartan | Drug Info | High blood pressure [ICD-11: BA00] | Approved | [26] | |
Clinical Trial Drug(s) Transported by This DT | Benzylpenicillin | Drug Info | Gram-positive bacteria infections [ICD-11: 1A00-1H0Z] | Phase 4 | [8] |
M17055 | Drug Info | Diuretic vasodilator [ICD-11: BA00] | Phase 3 | [27] | |
Talinolol | Drug Info | Gastrointestinal motility disorder [ICD-11: DE2Z] | Phase 1 | [28] | |
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT | Scutellarin | Drug Info | Cerebrovascular ischaemia [ICD-11: 8B1Z] | Preclinical | [29] |
Sodium taurocholate | Drug Info | Type 2 diabetes [ICD-11: 5A11] | Preclinical | [22] | |
Taurocholic acid | Drug Info | Type 2 diabetes [ICD-11: 5A11] | Terminated | [22] | |
Endogenous Substrate(s) | Organoanions | ||||
Drug-DT Affinity Assessed by Cell Line | |||||
Drug(s) with Drug-DT Affinity Data | Atorvastatin | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 2.84 microM | [30] |
Atorvastatin | Drug Info | Madin-Darby canine kidney cells (MDCKII)-OATP2B1 | Km = 0.2 microM | [31] | |
Bosentan | Drug Info | Chinese hamster ovary (CHO) cells-OATP2B1 | Km = 202 microM | [4] | |
Bromsulphthalein | Drug Info | Oocytes-OATP2B1 | Km = 0.7 microM | [32] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 1.56 microM | [33] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 7.14 microM | [13] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 8.09 microM | [22] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 10.2 microM | [10] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 12.5 microM | [34] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 13.1 microM | [22] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 20.9 microM | [21] | |
Estrone sulfate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 38.24 microM | [30] | |
Estrone sulfate | Drug Info | Human enterocyte-like 2 cells (Caco-2)-OATP2B1 | Km = 1.81 microM | [33] | |
Estrone sulfate | Drug Info | Oocytes-OATP2B1 | Km = 6.3 microM | [32] | |
Fluvastatin | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 0.75 microM | [10] | |
Glibenclamide | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 6.26 microM | [13] | |
Mesalazine | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 188.9 microM | [17] | |
Pitavastatin calcium | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 1.17 microM | [21] | |
Pravastatin | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 2250 microM | [22] | |
Rosuvastatin | Drug Info | Human cervical cancer cell line (Hela)-OATP2B1 | Km = 2.4 microM | [35] | |
Rosuvastatin | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 6.42 microM | [24] | |
Sodium taurocholate | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 71.8 microM | [22] | |
Taurocholic acid | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 71.8 microM | [22] | |
Telmisartan | Drug Info | Human embryonic kidney cells (HEK293)-OATP2B1 | Km = 1.09 microM | [26] | |
References | |||||
1 | The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311. | ||||
2 | Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26. | ||||
3 | Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37. | ||||
4 | Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7. | ||||
5 | pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13. | ||||
6 | Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372. | ||||
7 | Drug Interactions in Infectious Diseases. | ||||
8 | Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. | ||||
9 | Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96. | ||||
10 | Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14. | ||||
11 | Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847. | ||||
12 | The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93. | ||||
13 | Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. | ||||
14 | The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20) | ||||
15 | The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. | ||||
16 | Clinical Pharmacology and Biopharmaceutics review(s) | ||||
17 | Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102. | ||||
18 | Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93. | ||||
19 | Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42. | ||||
20 | Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171-9. | ||||
21 | Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36. | ||||
22 | Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. | ||||
23 | pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22. | ||||
24 | Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23. | ||||
25 | Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694. | ||||
26 | Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805. | ||||
27 | Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 2007 Jan;24(1):90-8. | ||||
28 | Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9. | ||||
29 | Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20. | ||||
30 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. | ||||
31 | Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006 Dec;80(6):607-20. | ||||
32 | Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. | ||||
33 | Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 2006 Aug;34(8):1423-31. | ||||
34 | Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. | ||||
35 | Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.